NextCure, Inc.

    Jurisdiction
    United States
    LEI
    549300Y5PR6RJR1STI24
    ISIN
    US65343E2072 (NXTC)
    Sectors
    1. Healthcare
    2. Biotechnology

    Scores

    InsiderPie Expert Score
    trending_flat 50 / 100
    Even with peer group:
    50 / 100
    Fair value (Benjamin Graham formula)
    N/A
    Financial strength (Piotroski F-Value)
    2 / 9
    Fundamental strength relative to industry (Mohanram G-Value)
    4 / 7

    Profile

    NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Read full profile

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Fundamentals

    Net revenue
    €0.00
    Gross margin
    0.0%
    EBIT
    -€55.29M
    EBIT margin
    0.0%
    Net income
    -€52.75M
    Net margin
    0.0%

    Statement period: - (published )

    Dividends

    No dividend payouts

    Investor transactions

    Name Shares Value Last change Change type
    Peter Brown 480K $230.53K -3.3K Sell

    Add to watchlist

    Notifications